Hans Peter Hasler is a senior executive and top-level advisor to the life-sciences industry. He has an international track record and in-depth operational, commercial, and general management expertise. During his career, Mr. Hasler has managed the growth of leading players in the pharmaceutical industry and has successfully launched several blockbuster drugs.
Mr. Hasler has a broad network at the executive level with a high number of pharmaceutical and biotechnology corporations. He is Chairman of the Board of HBM Healthcare Investments AG in Switzerland; Director of the Board of Minerva Neuroscience Inc., Boston; Member of the Board of Shield Therapeutics plc, London; and Chief Advisor of SBTech Advisory, a small asset scouting company located in Israel, Switzerland, and the USA.
Mr. Hasler is founder and CEO of Vicarius Pharma. The company develops and executes successful European go-to-market strategies for specialty, rare/orphan, and hospital products.
Global Life Sciences Advisor, Switzerland
Chief Executive Officer, Vicarius Pharma, Switzerland
Chief Operating Officer, Elan Pharmaceuticals, Ireland/Switzerland
Chief Operating Officer, Biogen, USA/Switzerland
Head of Commercial Operations, Biogen, USA
SVP, Biogen, Switzerland
Chief Marketing Officer, Wyeth, USA
Managing Director, Wyeth, Germany
General Manager, Wyeth, Switzerland/Austria/CEE
German, English, French
Chairman of the Board, HBM Healthcare Investments, Switzerland
Member of the Board, Shield Therapeutics plc, London
Director of the Board, Minerva Neuroscience Inc., Boston
Chairman of the Board, Medical Imaging Analysis Center (MIAC), University Hospital Basel, Switzerland